Recent prospective evidence suggests that carriers of pathogenic MSH2 variants in particular have an increased risk of prostate cancer (PrC) relative to the general population, and a slight increase in breast cancer (BC) risk has been observed irrespective of which MMR gene is affected [2]. This evidence concerns the gene MSH2 and breast cancer.